Regeneron drug halves muscle loss with Novo's semaglutide in trial
An experimental weight-loss drug developed by Regeneron (REGN), when combined with Novo Nordisk's (NOVO_B) semaglutide, reduced muscle mass loss by 50% compared to semaglutide alone in a study of obese patients, according to trial data.
Story updates
10:30:15 PM UTC
SquawkNews
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial
An experimental weight-loss drug being developed by Regeneron NASDAQ:REGN, when used together with Novo Nordisk's OMXCOP:NOVO_B semaglutide, cut muscle-mass loss by 50% versus semaglutide alone in a study of patients with obesity, according to data.